Expert Consensus on Diagnosis and Molecular Testing Strategies for Non-Small-Cell Lung Cancer in India

Bivas Biswas; Trupti Pai; Nirmal Raut; Vidya Manur Narasimhamurthy; Bijal Kulkarni; Ashish Singh; Sunil Pasricha; Jayesh Deshmukh; Sewanti Limaye

doi:10.1055/s-0045-1809375

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1809375

Review Article

Expert Consensus on Diagnosis and Molecular Testing Strategies for Non-Small-Cell Lung Cancer in India

Bivas Biswas

¹Department of Oncology, Apollo Multispecialty Hospital, Kolkata, West Bengal, India

,

Trupti Pai

²Department of Pathology, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Nirmal Raut

³Department of Oncology, Bhaktivedanta Hospital & Research Centre, Mira-Bhayandar, Maharashtra, India

,

Vidya Manur Narasimhamurthy

⁴Department of Pathology, Manipal Hospitals, Bengaluru, Karnataka, India

,

Bijal Kulkarni

⁵Department of Histopathology and Cytology, Cytogenetics - Laboratory Medicine, Kokilaben Dhirubhai Ambani Hospital, Andheri, Mumbai, Maharashtra, India

,

Ashish Singh

⁶Department of Oncology, Christian Medical College, Vellore, Tamil Nadu, India

,

Sunil Pasricha

⁷Department of Pathology, Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, Delhi, India

,

Jayesh Deshmukh

⁸Department of Medical and Scientific Affairs, Roche Diagnostics India, Mumbai, Maharashtra, India

,

Sewanti Limaye

⁹Department of Oncology, Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India

› Institutsangaben

Abstract

This review aims to establish expert consensus on biomarker testing for non-small-cell lung cancer (NSCLC) in India, evaluating diagnostic practices, adherence to international guidelines, and test utility and comparing clinically validated assays with laboratory-developed tests. In round 1, experts voted on 41 statements covering various aspects of NSCLC diagnostics. Responses were graded using a 5-point Likert scale, categorizing agreement levels as high, moderate, or low based on expert consensus percentages. After thorough deliberations during round 2, consensus was reached on 32 statements underscoring the necessity for early diagnosis of NSCLC. Key issues include misdiagnosis with tuberculosis and low or delayed specialist referral rates. Although formal programs are limited by awareness, resources, and data gaps; low-dose computed tomography (LDCT) screening in community settings is advocated. Consensus was reached among experts that most lung cancers are diagnosed at advanced stages in India. The delay in diagnosis was mainly due to misdiagnosis with tuberculosis and delayed referrals to specialists for evaluation. The consensus acknowledged the need to enhance lung cancer awareness and utilization of LDCT in high-risk individuals as a screening methodology in the community.

Biomarker testing for both early-stage and advanced-stage NSCLC is recommended, with reflex testing at diagnosis, longitudinal testing at disease progression, and liquid biopsies when tissue is unavailable/inadequate. Biomarker testing for common driver mutations associated with available targeted therapies can be performed in resource-limited settings using sequential testing or hotspot panels. PD-L1 testing for all advanced-stage cases is recommended, especially when molecular driver mutations/fusions are negative. Despite longer turnaround times, next-generation sequencing (NGS) would be preferred for its comprehensive gene assessment. Multigene assays are recommended for advanced stages, and upfront broad-panel tests are ideal. Testing for EGFR, ALK, proto-oncogene ROS1, and PD-L1 is essential for NSCLC. We urge standardized histopathological and molecular practices and acknowledge challenges in NGS availability and the complexities of interpreting results. This consensus underscores the importance of streamlined approaches to enhance NSCLC diagnostics in resource-constrained settings in India.

Keywords

non-small-cell lung cancer - next-generation sequencing - biomarkers - companion diagnostic - reflex testing - targeted therapies - low-dose computed tomography

Volltext

Referenzen

References
1 Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Accessed May 27, 2024 at: https://gco.iarc.who.int/today
2 Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol 2024; 93: 102693
3 Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian J Med Res 2022; 156 (4 & 5): 598-607
4 Alduais Y, Zhang H, Fan F, Chen J, Chen B. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment. Medicine (Baltimore) 2023; 102 (08) e32899
5 Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019; 94 (08) 1623-1640
6 Nath A, Sathishkumar K, Das P, Sudarshan KL, Mathur P. A clinicoepidemiological profile of lung cancers in India - results from the National Cancer Registry Programme. Indian J Med Res 2022; 155 (02) 264-272
7 Ninatti G, Kirienko M, Neri E, Sollini M, Chiti A. Imaging-based prediction of molecular therapy targets in NSCLC by radiogenomics and AI approaches: a systematic review. Diagnostics (Basel) 2020; 10 (06) 359
8 Singh N, Agrawal S, Jiwnani S. et al. Lung cancer in India. J Thorac Oncol 2021; 16 (08) 1250-1266
9 Mohan A, Garg A, Gupta A. et al. Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India 2020; 37 (03) 190-197
10 National Cancer Institute. SEER cancer stat facts: lung and bronchus cancer. Accessed May 29, 2024 at: https://seer.cancer.gov/statfacts/html/lungb.html
11 Mitsudomi T, Tan D, Yang JC. et al. Expert consensus recommendations on biomarker testing in metastatic and nonmetastatic NSCLC in Asia. J Thorac Oncol 2023; 18 (04) 436-446
12 Central Drugs Standard Control Organization. New drugs approved by CDSCO. Accessed Feb 6, 2024 at: https://cdscoonline.gov.in/CDSCO/Drugs
13 U.S. Food and Drug Administration. . Drug approvals and databases. Accessed Feb 6, 2024 at: https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases
14 Mazzone PJ, Sears CR, Arenberg DA. et al; ATS Assembly on Thoracic Oncology. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American Thoracic Society Policy Statement. Am J Respir Crit Care Med 2017; 196 (07) e15-e29
15 Conde E, Rojo F, Gómez J. et al. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. J Clin Pathol 2022; 75 (03) 145-153
16 Ettinger DS, Wood DE, Aisner DL. et al. Non-small cell lung cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20 (05) 497-530
17 Lindeman NI, Cagle PT, Aisner DL. et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol 2018; 13 (03) 323-358
18 Hendriks LE, Kerr KM, Menis J. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (04) 339-357
19 Prabhash K, Advani SH, Batra U. et al. Biomarkers in non-small cell lung cancers: Indian Consensus Guidelines for Molecular Testing. Adv Ther 2019; 36 (04) 766-785
20 Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to decide its appropriateness. World J Methodol 2021; 11 (04) 116-129
21 Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine: levels of evidence (March 2009). Accessed February 6, 2024 at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009
22 Vashistha V, Choudhari C, Garg A. et al. The time required to diagnose and treat lung cancer in Delhi, India: an updated experience of a public referral center. Appl Cancer Res 2019; 39: 11
23 Osarogiagbon RU, Liao W, Faris NR. et al. Lung cancer diagnosed through screening, lung nodule, and neither program: a prospective observational study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort. J Clin Oncol 2022; 40 (19) 2094-2105
24 Shankar A, Saini D, Dubey A. et al. Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. Transl Lung Cancer Res 2019; 8 (Suppl. 01) S106-S121
25 Crane M, Scott N, O'Hara BJ. et al. Knowledge of the signs and symptoms and risk factors of lung cancer in Australia: mixed methods study. BMC Public Health 2016; 16: 508
26 Fu F, Zhou Y, Zhang Y, Chen H. Lung cancer screening strategy for non-high-risk individuals: a narrative review. Transl Lung Cancer Res 2021; 10 (01) 452-461
27 Aberle DR, Adams AM, Berg CD. et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365 (05) 395-409
28 Teles GBDS, Macedo ACS, Chate RC, Valente VAT, Funari MBG, Szarf G. LDCT lung cancer screening in populations at different risk for lung cancer. BMJ Open Respir Res 2020; 7 (01) e000455
29 Poon C, Wilsdon T, Sarwar I, Roediger A, Yuan M. Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption. Front Public Health 2023; 11: 1264342
30 Biswas B, Talwar D, Meshram P. et al. Navigating patient journey in early diagnosis of lung cancer in India. Lung India 2023; 40 (01) 48-58
31 Vora A, Balamugesh T, Behera D. et al. Screening for lung cancer in India: expert opinion statement. J Assoc Physicians India 2024; 72 (05) e1-e16
32 Parang S, Bhavin J. LDCT screening in smokers in India-a pilot, proof-of-concept study. Indian J Radiol Imaging 2021; 31 (02) 318-322
33 Gosney JR, Paz-Ares L, Jänne P. et al. Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation. ESMO Open 2023; 8 (04) 101587
34 Cheema PK, Menjak IB, Winterton-Perks Z. et al. Impact of reflex EGFR/ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer. J Oncol Pract 2017; 13 (02) e130-e138
35 Nambirajan A, Husain N, Shukla S, Kumar S, Jain D. Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma. Indian J Med Res 2019; 150 (04) 376-384
36 Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book 2019; 39: 531-542
37 Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res 2019; 8 (03) 286-301
38 Nakra T, Mehta A, Bal A. et al. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: multi-institutional data discussion at national conference of “Lung Cancer Management in Indian context”. Curr Probl Cancer 2020; 44 (03) 100561
39 Wu YL, Sequist LV, Hu CP. et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer 2017; 116 (02) 175-185
40 Raez LE, Brice K, Dumais K. et al. Liquid biopsy versus tissue biopsy to determine front line therapy in metastatic non-small cell lung cancer (NSCLC). Clin Lung Cancer 2023; 24 (02) 120-129
41 Papadopoulou E, Tsoulos N, Tsantikidi K. et al. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. PLoS One 2019; 14 (12) e0226853
42 Uruga H, Mino-Kenudson M. ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients. Pharm Genomics Pers Med 2018; 11: 147-155
43 Nambirajan A, Sood R, Khatoon W, Malik PS, Mohan A, Jain D. Concordance of immunohistochemistry and fluorescence in situ hybridization in the detection of anaplastic lymphoma kinase (ALK) and Ros proto-oncogene 1 (ROS1) gene rearrangements in non-small cell lung carcinoma: a 4.5-year experience highlighting challenges and pitfalls. Arch Pathol Lab Med 2024; 148 (08) 928-937
44 Godre N, Gupta V, Alam M. Concordance analysis of IHC and FISH in the detection of ROS1 gene rearrangement in NSCLC: results of a meta-analysis. ESMO 2017; 28: X140-X141
45 Koyama K, Miura S, Watanabe S. et al. Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. Sci Rep 2022; 12 (01) 6367
46 Prince EA, Sanzari JK, Pandya D, Huron D, Edwards R. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis Oncol 2021; 5: 953-973
47 Maule JG, Clinton LK, Graf RP. et al. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. J Immunother Cancer 2022; 10 (10) e005573
48 Franzi S, Seresini G, Borella P. et al. Liquid biopsy in non-small cell lung cancer: a meta-analysis of state-of-the-art and future perspectives. Front Genet 2023; 14: 1254839
49 de Jager VD, Timens W, Bayle A. et al. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. Lancet Reg Health Eur 2024; 38: 100839
50 Shukla S, Pandey RK, Kant S. et al. Detection of anaplastic lymphoma kinase gene re-arrangement in non-small cell lung carcinoma in the Indian population: comparison of techniques and immunohistochemistry clones. Turk Patoloji Derg 2019; 35 (01) 36-45
51 Nesline MK, Subbiah V, Previs RA. et al. The impact of prior single-gene testing on comprehensive genomic profiling results for patients with non-small cell lung cancer. Oncol Ther 2024; 12 (02) 329-343
52 Dall'Olio FG, Conci N, Rossi G. et al. Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients - a single centre experience. Lung Cancer 2020; 149: 5-9
53 Rolfo C, Mack PC, Scagliotti GV. et al. Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 2018; 13 (09) 1248-1268
54 Malapelle U, Tiseo M, Vivancos A, Kapp J, Serrano MJ, Tiemann M. Liquid biopsy for biomarker testing in non-small cell lung cancer: a European perspective. J Mol Pathol 2021; 2: 255-273
55 Li W, Liu JB, Hou LK. et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer 2022; 21 (01) 25
56 Smeltzer MP, Wynes MW, Lantuejoul S. et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol 2020; 15 (09) 1434-1448
57 Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 2019; 20 (02) 71-88
58 Bonanno L, Dal Maso A, Pavan A. et al. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?. Br J Cancer 2022; 127 (03) 383-393
59 Li MSC, Mok KKS, Mok TSK. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review. Ann Transl Med 2023; 11 (10) 358
60 Murthy SS, Rajappa SJ, Gundimeda SD. et al. Anaplastic lymphoma kinase status in lung cancers: an immunohistochemistry and fluorescence in situ hybridization study from a tertiary cancer center in India. Indian J Cancer 2017; 54 (01) 231-235
61 Doval D, Prabhash K, Patil S. et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. OncoTargets Ther 2015; 8: 117-123
62 Saw SPL, Zhong WZ, Fu R. et al. Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancer. Lung Cancer 2025; 200: 108076
63 Aguiar Jr PN, De Mello RA, Hall P, Tadokoro H, Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy 2017; 9 (06) 499-506
64 Vallonthaiel AG, Malik PS, Singh V. et al. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India. Ann Diagn Pathol 2017; 31: 56-61
65 Batra U, Nathany S. Biomarker testing in lung cancer: from bench to bedside. Oncol Rev 2025; 18: 1445826
66 Owen D, Ben-Shachar R, Feliciano J. et al. Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer. JAMA Netw Open 2024; 7 (11) e2442970
67 Desmeules P, Boudreau DK, Bastien N. et al. Performance of an RNA-based next-generation sequencing assay for combined detection of clinically actionable fusions and hotspot mutations in NSCLC. JTO Clin Res Rep 2022; 3 (02) 100276
68 Zheng Y, Vioix H, Liu FX, Singh B, Sharma S, Sharda D. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review. Future Oncol 2022; 18 (04) 505-518
69 Mathew A, Joseph S, Boby J. et al. Clinical benefit of comprehensive genomic profiling for advanced cancers in India. JCO Glob Oncol 2022; 8: e2100421
70 Schmid S, Jochum W, Padberg B. et al. How to read a next-generation sequencing report-what oncologists need to know. ESMO Open 2022; 7 (05) 100570
71 Amrith B, Sharma M, Jain P. et al. NGS in advanced NSCLC in a developing country: ready for prime time?. ESMO 2019; 30 (09) ix127
72 Mehta A, Vasudevan S, Sharma S. et al. Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape. Appl Cancer Res 2020; 40: 1-12
73 Batra U, Nathany S, Sharma M. et al. 395P Molecular landscape of Indian NSCLC: is NGS the answer?. Ann Oncol 2022; 33: S1596
74 Gupta P, Saha K, Vinarkar S. et al. Next generation sequencing in lung cancer: an initial experience from India. Curr Probl Cancer 2020; 44 (03) 100562-100573
75 Perdrizet K, Stockley TL, Law JH. et al. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. Cancer Treat Res Commun 2022; 31: 100534-100541

Zusatzmaterial

Supplementary Material